LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Home・Akciju saraksts・Krystal Biotech Inc

Krystal Biotech Inc

Slēgts

SektorsVeselības aprūpe

250.16 -1.77

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

250

Max

256.35

Galvenie mērījumi
By Trading Economics
Ienākumi	-28M 51M
Pārdošana	9.3M 107M
P/E Sektora vidējais	36.627 57.833
Peļņas marža	47.99
Darbinieki	295
EBITDA	-10M 40M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+26.52% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-704M 7.3B
Iepriekšējā atvēršanas cena	251.93
Iepriekšējā slēgšanas cena	250.16

Ziņu noskaņojums

By Acuity

25%

75%

57 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

133.221 / 169.73 Atbalsts un pretestība

Krystal Biotech Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. marts 22:51 UTC

Peļņas

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

2026. g. 18. marts 21:40 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

2026. g. 18. marts 20:31 UTC

Peļņas

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

2026. g. 18. marts 23:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

2026. g. 18. marts 23:31 UTC

Tirgus saruna

Gold Rises on Likely Technical Recovery -- Market Talk

2026. g. 18. marts 22:49 UTC

Tirgus saruna

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

2026. g. 18. marts 22:41 UTC

Tirgus saruna

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

2026. g. 18. marts 22:36 UTC

Peļņas

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

2026. g. 18. marts 22:24 UTC

Peļņas

AIA Group Announces New Share Buyback of $1.7B >1299.HK

2026. g. 18. marts 22:23 UTC

Peļņas

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

2026. g. 18. marts 22:23 UTC

Peļņas

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

2026. g. 18. marts 21:58 UTC

Peļņas

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

2026. g. 18. marts 21:55 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2026. g. 18. marts 21:55 UTC

Tirgus saruna

Peļņas

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

2026. g. 18. marts 21:40 UTC

Tirgus saruna

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

2026. g. 18. marts 21:16 UTC

Tirgus saruna

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

2026. g. 18. marts 21:00 UTC

Galvenie ziņu notikumi

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

2026. g. 18. marts 20:58 UTC

Peļņas

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

2026. g. 18. marts 20:41 UTC

Peļņas

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026. g. 18. marts 20:29 UTC

Peļņas

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026. g. 18. marts 20:25 UTC

Peļņas

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026. g. 18. marts 20:17 UTC

Peļņas

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

2026. g. 18. marts 20:14 UTC

Tirgus saruna

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

2026. g. 18. marts 20:09 UTC

Peļņas

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

2026. g. 18. marts 20:07 UTC

Peļņas

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

2026. g. 18. marts 20:06 UTC

Peļņas

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

2026. g. 18. marts 20:04 UTC

Peļņas

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

2026. g. 18. marts 20:04 UTC

Peļņas

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

2026. g. 18. marts 20:04 UTC

Peļņas

Micron Technology Sees 3Q Gross Margin About 81% >MU

2026. g. 18. marts 20:03 UTC

Peļņas

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Salīdzinājums

Cenas izmaiņa

Krystal Biotech Inc Prognoze

Cenas mērķis

By TipRanks

26.52% augšup

Prognoze 12 mēnešiem

Vidējais 324.3 USD 26.52%

Augstākais 371 USD

Zemākais 284 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Krystal Biotech Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Krystal Biotech Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

133.221 / 169.73Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

Noskaņojums

By Acuity

57 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.